Co-Diagnostics, Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology Co-Diagnostics agrees to license CoPrimers for use in agricultural applications Salt Lake City, Utah

Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology

agrees to license CoPrimers for use in agricultural applications

Lake City, Utah - October 30, 2018 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique,

proprietary platform for the development of molecular diagnostic tests, and LGC, Biosearch Technologies, a global leader in

the design, development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied

markets, announced today that they have signed an exclusive license agreement related to

the use of the Company's CoPrimer technology for both research and commercial applications.

Agreement is the result of a joint development project conducted over the past year to test the performance of CoPrimers in multiplexed

reactions when locating specific genetic traits in seed products and genetic mutations, including SNP detection.

Egan, CEO of Co-Diagnostics, commented, "The importance of the validation for our company and technology provided by this

license agreement cannot be overstated. We believe the participation of an industry leading portfolio like Biosearch Technologies

speaks volumes about the quality and uniqueness of our CoPrimer platform technology. As Biosearch Technologies clients begin to

adopt our technology under the terms of this agreement, we

look forward to offering our CoDX Design Services to help streamline and improve their operations, as

well as to introducing them to further applications of CoPrimers to widen our customer base.

anticipates this to be the first of many CoPrimer technology license agreements where the accuracy, time- and cost-saving advantages

of true multiplex polymerase chain reaction ("PCR"), without concern of cross-reactivity among primer sets leading

to inaccurate results, is critical for the application. We expect that the results of the research and proofs of concept we have

demonstrated throughout the course of the development project will have direct applications to any business, industry, or institution

that relies on PCR technology, and that all such industries will benefit from an improved, better PCR."

Dearden, VP Strategy and Marketing, LGC, Biosearch

Technologies, said, "The addition of the CoPrimer technology to our portfolio

demonstrates our commitment to apply innovative technologies that drive workflow efficiencies and enable our customers to achieve

more. We believe the CoPrimer technology overcomes many of the traditional shortfalls of multiplex PCR, and are confident our

customers will also realize the added flexibility and scalability this technology can bring to their businesses. The technology

is highly complementary to our existing oligonucleotide and PCR reagent portfolio, and aligns with our strategy to develop highly

innovative, mission critical tools in this space.

this Agreement covers the core CoPrimer technology for PCR applications, we are excited about the growing partnership with Co-Diagnostics.

LGC is hopeful our expertise in automation, reagents, and oligonucleotides will help expand the applications for the CoPrimer

technology, and look forward to future collaborations with Co-Diagnostics."

Technologies, the complete genomics portfolio from LGC, operates from cGMP and ISO 13485:2016 certified production facilities

and has been the sole manufacturer of Co-Diagnostics' CoPrimers since 2013.

is an international leader in the extended life sciences sector, including human healthcare, agri-food & the environment.

LGC provides a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation,

as well as research and measurement services. Its scientific tools and solutions enable organisations to advance research, develop

new products and form an essential part of their quality and compliance procedures.

Dearden is available for interview. Biosearch Technologies' logo and pictures available on request.

is an international leader in the extended life sciences sector, including human healthcare, agri-food & the environment.

LGC provides a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation,

as well as research and measurement services. Its scientific tools and solutions enable organisations to advance research, develop

new products and form an essential part of their quality and compliance procedures.

2,300 employees include internationally-recognized scientists who are experts in their field. Headquartered in London, it operates

out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043,

ISO/IEC 17025 and ISO 9001.

has been home to the UK Government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated

Institute for chemical and bio measurement. LGC has been privately-owned since 1996 and has diversified through internal investment

and acquisition to be an international leader in its chosen niche markets. LGC is now owned by funds affiliated with KKR.

more information, please visit www.lgcgroup.com

Relations & Social Media Manager

Co-Diagnostics, Inc.

Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics

technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic

acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers

for use in industries other than infectious disease and license the use of those tests to specific customers.

press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes,"

"expects," "estimates," "intends," "may," "plans," "will" and similar

expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at

the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release

include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives

in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital resources

and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii) flexibility

in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide

accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject

to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or

anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any

forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to

matters discussed in this press release, except as may be required by applicable securities laws.